Shots:

• Regeneron reports first data of seamless P-I/II/III study assessing REGN-COV2 that demonstrated a reduction in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. It also reduces the medical visit
• The descriptive analysis assesses REGN-COV2 (8gm/ 2.4gm) vs PBO in the first 275 patients enrolled in the trial in a ratio (1:1:1).  The trial suggested that REGN-COV2 could help patients whose own immune system is not strong enough to combat the virus
• In seronegative patients- the median time to symptom relief is (8/6days vs 13days)- rapid reduction in viral load. Regeneron believes its dual-antibody formula will limit the ability of the virus to escape detection and attack

­ Ref: Regeneron | Image: Asia News